X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
INDOCO REMEDIES LTD. Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

INDOCO REMEDIES LTD.  (INDOCO)


Here is the latest financial fact sheet of Indoco Remedies. For more details, see the Indoco Remedies quarterly results and Indoco Remedies share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
indoco remedies - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 252.8       No. of shares m 92.18
    Mkt Cap Rs m 23,297       % ch % -0.9
    Vol '000 1.6       % ch week % -2.0
    P/E X 29.3       % ch 1-mth % -5.9
    P/CF X 16.3       % ch 12-mth % -9.7
    EPS (TTM) Rs 8.6       52 week H/L Rs 360.4/250.1
(As on Mar 30, 2017 03:35:00 PM) »  Best Performing miscellaneous Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-12
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs48583162378412 
Low Rs3605155131263 
Sales per share (Unadj.) Rs462.868.579.593.0108.9 
Earnings per share (Unadj.) Rs37.74.66.39.09.0 
Diluted earnings per shareRs5.04.66.39.09.0 
Cash flow per share (Unadj.) Rs53.47.29.614.115.6 
Dividends per share (Unadj.) Rs1.101.101.401.601.60 
Adj. dividends per shareRs0.151.101.401.601.60 
Dividend yield (eoy) %0.31.61.30.60.5 
Book value per share (Unadj.) Rs309.244.949.656.363.4 
Adj. book value per shareRs41.244.949.656.363.4 
Shares outstanding (eoy) m12.2992.1592.1592.1592.15 
Bonus/Rights/Conversions  -FV2, B1:2--- 
Price / Sales ratio x0.91.01.42.73.1 
Avg P/E ratio x11.214.517.228.337.5 
P/CF ratio (eoy) x7.99.311.218.021.7 
Price / Book Value ratio x1.41.52.24.55.3 
Dividend payout %2.923.722.217.817.8 
Avg Mkt Cap Rs m5,1936,1749,98923,43831,087 
No. of employees `000NANANANA5.7 
Total wages/salary Rs m8191,0791,2951,4001,826 
Avg. sales/employee Rs ThNMNMNMNM1,754.8 
Avg. wages/employee Rs ThNMNMNMNM319.3 
Avg. net profit/employee Rs ThNMNMNMNM145.1 
  INCOME DATA
Net Sales Rs m5,6886,3087,3268,57010,038 
Other income Rs m2315181711 
Total revenues Rs m5,7106,3237,3448,58710,049 
Gross profit Rs m8469261,2041,6551,723 
Depreciation Rs m193237309471604 
Interest Rs m163219189106125 
Profit before tax Rs m5134867231,0961,006 
Minority Interest Rs m00-100 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m4958143267176 
Profit after tax Rs m464427580828830 
Gross profit margin %14.914.716.419.317.2 
Effective tax rate %9.611.919.824.417.5 
Net profit margin %8.16.87.99.78.3 
  BALANCE SHEET DATA
Current assets Rs m2,6202,7553,0463,8544,632 
Current liabilities Rs m1,8231,9932,0222,6212,887 
Net working cap to sales %14.012.114.014.417.4 
Current ratio x1.41.41.51.51.6 
Inventory Days Days6554556460 
Debtors Days Days7374696669 
Net fixed assets Rs m3,3423,5923,6944,0224,296 
Share capital Rs m123184184184184 
"Free" reserves Rs m3,6703,9504,3804,9955,650 
Net worth Rs m3,8004,1424,5725,1885,843 
Long term debt Rs m462274138129397 
Total assets Rs m6,5166,9197,2948,4569,638 
Interest coverage x4.13.24.811.49.0 
Debt to equity ratio x0.10.1000.1 
Sales to assets ratio x0.90.91.01.01.0 
Return on assets %9.69.310.511.09.9 
Return on equity %12.210.312.716.014.2 
Return on capital %15.915.919.422.618.1 
Exports to sales %34.533.533.936.240.3 
Imports to sales %6.85.45.47.57.7 
Exports (fob) Rs m1,9602,1162,4803,1014,044 
Imports (cif) Rs m389343396643773 
Fx inflow Rs m1,9602,1162,4803,1014,044 
Fx outflow Rs m4754455498191,017 
Net fx Rs m1,4851,6711,9312,2823,027 
  CASH FLOW
From Operations Rs m 691 687 988 1,090 1,133 
From Investments Rs m -639 -426 -410 -884 -1,120 
From Financial Activity Rs m -174 -244 -590 -199 -15 
Net Cashflow Rs m -122 17 -12 7 -1 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for indoco remedies ltd.

 Share Holding
Indian Promoters : 59.2%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 12.5%
FIIs : 6.0%
ADR/GDR : 0.0%
Free float : 22.4%
Shareholders : 12,805
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: 166, Indoco House, CST Road, kalina, Santacruz (E), Mumbai - 400 098
    E-MAIL: sunil.joshi@indoco.com     WEB: www.indoco.com
    TELEPHONE: (022) 2654 1851     FAX: (022) 2652 3067
    SECTOR: MISCELLANEOUS     GROUP: MISCELLANEOUS
    TR AGENT: Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
    AUDITOR: Patkar & Pendse
CHM: Suresh G. Kare (MD) COMP SEC: Sunil D. Joshi YEAR OF INC: 1945 BSE CODE: 532612 FV (Rs): 2 DIV YIELD (%): 0.6

More miscellaneous Company Fact Sheets:   UNICHEM LABSTRIDES SHASUN LTDNOVARTISAJANTA PHARMASUN PHARMA


Today's Market

Sensex Finishes Firm; Realty Stocks Rise(Closing)

Indian share markets finished the trading day on a firm note as the country moved a step closer to implementing a nationwide goods and services tax (GST) from July.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Bluechips Have 60% Chance Of Losing Money At Current Levels. But a Small Group Won't...(The 5 Minute Wrapup)

Mar 17, 2017

The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.

Doubled Your Money In D-Mart? Read This Before It's Too Late(Daily Profit Hunter)

Mar 22, 2017

Apurva breaks down the historic performance of initial public offerings in the context of D-Mart.

Why Real Estate Prices are Going Down at a Slow Pace(Vivek Kaul's Diary)

Mar 23, 2017

Many investors have got anchored to a selling price which has got nothing to do with the current state of the real estate market

Why Mutual Fund Investors Should Not Worry About Market High. But...(Outside View)

Mar 22, 2017

PersonalFN provides a prudent investment strategy to invest in mutual funds as market scales a new high.

Bad Loans Inventory Bloats Up(Chart Of The Day)

Mar 18, 2017

This is why RBI's new strategy is ineffective to deal with bad debt menace.

More

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - THOMAS COOK INDIA COMPARISON

Compare Company With Charts

COMPARE INDOCO REMEDIES WITH

MARKET STATS